Physostigmine treatment of progressive supranuclear palsy.
Cognitive and extrapyramidal effects of cholinomimetic therapy were evaluated in 8 patients with progressive supranuclear palsy. Each was randomized to a 10-day double-blind crossover trial of physostigmine and placebo. Physostigmine treatment was associated with marginal and inconsistent changes in long-term memory, suggesting that cholinergic therapy alone is insufficient to restore cognitive function. Motor scores remained unchanged.
Litvan
I
I
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20892.
Gomez
C
C
Atack
J R
JR
Gillespie
M
M
Kask
A M
AM
Mouradian
M M
MM
Chase
T N
TN
D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy / Q000209:etiology*; D008875:Middle Aged; D010830:Physostigmine / Q000627:therapeutic use*; D013494:Supranuclear Palsy, Progressive / Q000150:complications / Q000188:drug therapy*
D010830:Physostigmine